Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker SRCE
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Brett A. Bauer Treasurer and CFO | SRCE 1st Source Corporation | Sale | 500 | $87.89 | $43.9K Sale | Form 4 ↗ |
| Feb 13, 2026 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 51 | $69.14 | $3,535 Buy | Form 4 ↗ |
| Dec 15, 2025 | Jeffrey L. Buhr Executive Vice President | SRCE 1st Source Corporation | Sale | 1,175 | $66.14 | $77.7K Sale | Form 4 ↗ |
| Dec 10, 2025 | John B. Griffith Exec VP / Secy 1st Source Bank | SRCE 1st Source Corporation | Sale | 1,900 | $66.01 | $125.4K Sale | Form 4 ↗ |
| Nov 14, 2025 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 57 | $61.71 | $3,513 Buy | Form 4 ↗ |
| Aug 15, 2025 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 54 | $61.31 | $3,316 Buy | Form 4 ↗ |
| May 15, 2025 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 53 | $62.42 | $3,296 Buy | Form 4 ↗ |
| Feb 14, 2025 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 47 | $66.41 | $3,106 Buy | Form 4 ↗ |
| Nov 15, 2024 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 46 | $66.53 | $3,089 Buy | Form 4 ↗ |
| Aug 15, 2024 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 52 | $57.02 | $2,980 Buy | Form 4 ↗ |
| May 15, 2024 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 53 | $52.43 | $2,797 Buy | Form 4 ↗ |
| Feb 15, 2024 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 56 | $49.50 | $2,777 Buy | Form 4 ↗ |
| Nov 15, 2023 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 58 | $47.21 | $2,758 Buy | Form 4 ↗ |
| Aug 11, 2023 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 53 | $48.21 | $2,579 Buy | Form 4 ↗ |
| May 12, 2023 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 48 | $40.98 | $1,954 Buy | Form 4 ↗ |
| Feb 16, 2023 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 39 | $49.55 | $1,941 Buy | Form 4 ↗ |
| Nov 10, 2022 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 32 | $57.58 | $1,866 Buy | Form 4 ↗ |
| Aug 12, 2022 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 38 | $48.50 | $1,854 Buy | Form 4 ↗ |
| May 13, 2022 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 40 | $44.35 | $1,784 Buy | Form 4 ↗ |
| Feb 16, 2022 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 36 | $48.72 | $1,772 Buy | Form 4 ↗ |
| Nov 12, 2021 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 35 | $50.84 | $1,762 Buy | Form 4 ↗ |
| Aug 13, 2021 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 35 | $47.56 | $1,676 Buy | Form 4 ↗ |
| May 14, 2021 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 30 | $48.06 | $1,424 Buy | Form 4 ↗ |
| Feb 12, 2021 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 42 | — | $0 Buy | Form 4 ↗ |
| Nov 13, 2020 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 1 | — | $0 Buy | Form 4 ↗ |
| Aug 14, 2020 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 1 | — | $0 Buy | Form 4 ↗ |
| May 15, 2020 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 2 | — | $0 Buy | Form 4 ↗ |
| Feb 14, 2020 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 1 | — | $0 Buy | Form 4 ↗ |
| Nov 15, 2019 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 1 | — | $0 Buy | Form 4 ↗ |
| Aug 15, 2019 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 1 | — | $0 Buy | Form 4 ↗ |
| May 15, 2019 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 1 | — | $0 Buy | Form 4 ↗ |
| Feb 14, 2019 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 1 | — | $0 Buy | Form 4 ↗ |
| Nov 15, 2018 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 1 | — | $0 Buy | Form 4 ↗ |
| Aug 15, 2018 | Melody Birmingham Director | SRCE 1st Source Corporation | Buy | 1 | — | $0 Buy | Form 4 ↗ |
34 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:07 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances